DOI: https://dx.doi.org/10.18203/2320-6012.ijrms20222988
Published: 2022-11-25

Clinical dimensions of hypokinetic non-dilated cardiomyopathy in terms of severity and hospital outcome

Sibaram Panda, Sunil K. Sharma, Mayadhar Panda

Abstract


Background: Hypokinetic non-dilated cardiomyopathy [HNDC/DCM (ND-H)] is a recently proposed (by ESC, 2016) subtype of dilated cardiomyopathy (DCM), which is characterized by the absence of left ventricular (LV) dilatation despite of global LV systolic dysfunction. Knowledge regarding clinical severity and outcomes of patients with DCM (ND-H) is very limited. Objective of the study was to evaluate clinical severity and hospital outcome of patients with HNDC [DCM (ND-H)].

Methods: Total 1248 admitted patients with primary DCM were finalized as study participants considering inclusion and exclusion criteria. The study participants were categorized into two groups depending on presence or absence of LV dilatation. 411 (32.9%) patients without any LV dilatation included in group A [HNDC/DCM (ND-H) group] and 837 (67.1%) patients with LV dilatation included in group B [DCM (D-H) group]. Data with respect to clinical, electrocardiographic, echocardiographic findings and disease outcome of patients compared statistically between the two groups.

Conclusions: HNDC [DCM (ND-H)] is a subclinical subtype, which represents 1/3rd population of DCM. Apart from absence of cardiomegaly, typical clinical signs, electrocardiographic abnormalities, from which we can suspect heart disease, were less prevalent in patients with DCM (ND-H). Therefore, patient most often miss the diagnosis till the advance stage. Non cardiac co-morbidities along with late diagnosis can be important contributing factors for adverse clinical outcomes in patients with DCM (ND-H) comparable to the DCM (D-H) counterpart.


Keywords


DCM, DCM (ND-H), DCM (D-H), MR, S3

Full Text:

PDF

References


Keren A, Gottlieb S, Tzivoni D, Stinson EB, Popp RL. Mildly dilated congestive cardiomyopathy. Use of prospective diagnostic criteria and description of the clinical course without heart transplantation. Circulation. 1990;81:506-17.

Gavazzi A, De Maria R, Renosto G, Moro A, Borgia M, Caroli A, et al. The spectrum of left ventricular size in dilated cardiomyopathy: clinical correlates and prognostic implications. SPIC (Italian Multicenter Cardiomyopathy Study) Group. Am Heart J. 1993;125(2):410-22.

Cioffi G, Tarantini L, De Feo S, Pulignano G, Del Sindaco D, Stefenelli C, Opasich C. Dilated versus nondilated cardiomyopathy in the elderly population treated with guideline-based medical therapy for systolic chronic heart failure. J Card Fail. 2004;10(6):481-9.

Draper TS, Schick EC, Gaasch WH. Non-Dilated Cardiomyopathy: Changes in Left Ventricular Size and Function over Time and the Impact of Atrial Fibrillation. Cardiovascular Structure. 2009;15(6):S31.

Doumas A, Draper TS Jr, Schick EC, Gaasch WH. Prevalence and clinical characteristics of nondilated cardiomyopathy and the effect of atrial fibrillation. Am J Cardiol. 2010;105(6):884-7.

Gigli M, Stolfo D, Merlo M, Barbati G, Ramani F, Brun F, Pinamonti B, Sinagra G. Insights into mildly dilated cardiomyopathy: temporal evolution and long-term prognosis. Eur J Heart Fail. 2017;19(4):531-9.

Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37(23):1850-8.

Guo X, Li Z, Guo L, Yu S, Li T, Zheng L, Pan G, Yang J, Sun Y, Hui R, Pletcher MJ. Prevalence of hypokinetic non-dilated cardiomyopathy in a large general Chinese population. Int J Cardiol. 2016;223:708-710.

Sharma A, Zhao X, Hammill BG, Hernandez AF, Fonarow GC, Felker GM, et al. Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines-Heart Failure Registry. Circ Heart Fail. 2018;11(6):e004646.

Verdonschot JAJ, Hazebroek MR, Wang P, Sanders-van Wijk S, Merken JJ, Adriaansen YA, et al. Clinical Phenotype and Genotype Associations With Improvement in Left Ventricular Function in Dilated Cardiomyopathy. Circ Heart Fail. 2018;11(11):e005220.

Mombeini H, Parsaee M, Amin A. Speckle tracking echocardiography in hypokinetic non-dilated cardiomyopathy: comparison with dilated cardiomyopathy. ESC Heart Fail. 2020;7(4):1909-16.

Mohammed SF, Borlaug BA, Roger VL, Mirzoyev SA, Rodeheffer RJ, Chirinos JA, Redfield MM. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ Heart Fail. 2012;5(6):710-9.

Silverman ME. The Third Heart Sound. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd ed. Boston: Butterworths; 1990.

Gupta A, Sharma P, Bahletal A. Left ventricular size as a predictor of outcome in patients of non-ischemicdilated cardiomyopathy with severe left ventricular systolic dysfunction. Int J Cardiol. 2016;221:310-30.

Al-Amri HS, Al-Moghairi AM, El Oakley RM. Surgical treatment of functional mitral regurgitation in dilated cardiomyopathy. J Saudi Heart Assoc. 2011;23(3):125-34.

Takarada A, Yokota Y, Kumaki T, Toh S, Seo T, Kubo M, Maehashi N, Fujitani K, Furuta Y, Fukuzaki H. [Hypertensive heart disease simulating dilated cardiomyopathy]. J Cardiogr. 1985;15(4):1015-26.

Takarada A, Kurogane H, Hayashi T, Fujimoto T, Yasaka Y, Fukumoto Y, Shimatani Y, Yamakawa H, Sasaki S, Matsuura A, et al. Prognostic significance of atrial fibrillation in dilated cardiomyopathy. Jpn Heart J. 1993;34(6):749-58.